4basebio synthetic DNA powers tier 1 pharma IND filing for mRNA vaccine
Cambridge, UK, 07 August 2025: 4basebio PLC (AIM: 4BB) (“4basebio”), an innovation-led provider of novel synthetic DNA products, today announces that a Tier 1 pharmaceutical partner has received FDA approval for their Investigational New Drug (IND) application for an mRNA vaccine developed using 4basebio’s proprietary opDNA® template.
Dr. Heikki Lanckriet, 4basebio CEO, commented: “We are delighted to have supported this tier 1 pharma in their recent IND filing, which represents another major regulatory milestone for 4basebio and a clear signal of a growing industry adoption of synthetic DNA”
He adds “Following closely on from the recent GMP certification of our manufacturing facility, we see increasing commercial momentum as a growing number of client programs advance into the clinic.”
This IND filing follows a series of important milestones for 4basebio, including the recent GMP certification of its state-of-the-art manufacturing facility and strategic collaborations with pioneering biotech companies developing advanced genetic medicines. These achievements underscore 4basebio’s role as a trusted partner to the global biopharma industry, delivering high-quality synthetic DNA to power next-generation therapies.
Synthetic DNA represents a fundamental shift for the life sciences sector. Unlike traditional plasmid DNA, which is constrained by lengthy manufacturing, 4basebio’s opDNA® platform enables faster, scalable, and contamination free production of DNA templates. This breakthrough not only accelerates the development timelines for mRNA vaccines and gene therapies but also enhances safety and consistency, two critical factors for clinical success. By removing bottlenecks in DNA supply, 4basebio is enabling researchers and pharmaceutical companies to bring transformative therapies to patients more quickly, with the potential to change lives across infectious disease, oncology, and rare genetic disorders.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
About 4basebio
4basebio is a specialist life sciences company focused on the design, manufacture, and supply of synthetic DNA for use in applications such as gene therapies, mRNA therapies, and DNA vaccines. Its proprietary synthetic DNA platform enables scalable, pDNA-free manufacturing, supporting faster development and improved safety profiles for genetic medicines.
For more information, please visit www.4basebio.com or follow us on LinkedIn